Management options: Anthracycline-induced cardiomyopathy
نویسندگان
چکیده
منابع مشابه
Management options Anthracycline-induced cardiomyopathy
Anthracycline cardiomyopathy is less frequently encountered nowadays, due to the well-recognised dose limitations and cardiac monitoring protocols used by chemotherapy centres. However, it is a condition that will persist due to the sensitivity of some patients to these drugs and the necessity for large doses to be used for certain individuals. We have demonstrated the benefit of angiotensin-co...
متن کاملAnthracycline-induced cardiomyopathy in siblings with early breast cancer.
A 41-year-old woman with no significant previous medical or family history underwent a left wide local excision (WLE) and axillary node clearance for a 9-mm grade 3 IDC, node-negative breast cancer. The tumour was estrogen receptor (ER), progesterone receptor (PgR) and HER-2 negative. She received six cycles of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC 75, ...
متن کاملProtective effects of carvedilol against anthracycline-induced cardiomyopathy.
OBJECTIVES The aim of this study was to determine the protective effect of carvedilol in anthracycline (ANT)-induced cardiomyopathy (CMP). BACKGROUND Despite its broad effectiveness, ANT therapy is associated with ANT-induced CMP. Recent animal studies and experimental observations showed that carvedilol prevented development of CMP due to chemotherapeutics. However, there is no placebo-contr...
متن کاملEfficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy.
m g o d 0 m v s To the Editor: Antineoplastic agents of the anthracycline (ANT) group are commonly and effectively used in various forms of malignancies. Anthracyclines might lead to irreversible cardiomyopathy (CMP), despite their beneficial effects. A number of mechanisms, such as elevation in free superoxide anion radicals, apoptosis, and mitochondrial dysfunction have been implicated in ANT...
متن کاملCarvedilol for anthracycline cardiomyopathy prevention.
alay et al. (1), in a population of apparently unselected patients eceiving their first 6 cycles of anthracyclines, found in their ontrol group a high incidence of functional cardiomyopathy: 24% f their patients had at the final examination an ejection fraction of 0% or less. This incidence of cardiac dysfunction is higher than he expected one for patients beginning their exposure to anthraycli...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Postgraduate Medical Journal
سال: 1999
ISSN: 0032-5473
DOI: 10.1136/pgmj.75.883.265